147 related articles for article (PubMed ID: 29720732)
1. FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
Hu T; Wu Q; Chong Y; Qin H; Poole CJ; van Riggelen J; Ren M; Cowell JK
Leukemia; 2018 Nov; 32(11):2363-2373. PubMed ID: 29720732
[TBL] [Abstract][Full Text] [Related]
2. Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome.
Chong Y; Liu Y; Lu S; Cai B; Qin H; Chang CS; Ren M; Cowell JK; Hu T
Int J Cancer; 2020 Apr; 146(8):2243-2254. PubMed ID: 31525277
[TBL] [Abstract][Full Text] [Related]
3. miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the
Hu T; Chong Y; Lu S; Wang R; Qin H; Silva J; Kitamura E; Chang CS; Hawthorn L; Cowell JK
Cancer Res; 2018 Jul; 78(13):3522-3531. PubMed ID: 29735550
[TBL] [Abstract][Full Text] [Related]
4. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
[TBL] [Abstract][Full Text] [Related]
5. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Ren M; Qin H; Ren R; Tidwell J; Cowell JK
Cancer Res; 2011 Dec; 71(23):7312-22. PubMed ID: 21937681
[TBL] [Abstract][Full Text] [Related]
6. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract][Full Text] [Related]
7. The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase.
Hu T; Chong Y; Qin H; Kitamura E; Chang CS; Silva J; Ren M; Cowell JK
Oncogene; 2018 Apr; 37(14):1926-1938. PubMed ID: 29367757
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.
Malli T; Buxhofer-Ausch V; Rammer M; Erdel M; Kranewitter W; Rumpold H; Marschon R; Deutschbauer S; Simonitsch-Klupp I; Valent P; Muellner-Ammer K; Sebesta C; Birkner T; Webersinke G
Genes Chromosomes Cancer; 2016 Jan; 55(1):60-8. PubMed ID: 26391436
[TBL] [Abstract][Full Text] [Related]
9. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.
Ren M; Cowell JK
Blood; 2011 Jun; 117(25):6837-47. PubMed ID: 21527531
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
Ren M; Qin H; Ren R; Cowell JK
Leukemia; 2013 Jan; 27(1):32-40. PubMed ID: 22781593
[TBL] [Abstract][Full Text] [Related]
11. DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis.
Hu T; Chong Y; Cai B; Liu Y; Lu S; Cowell JK
J Biol Chem; 2019 Nov; 294(48):18122-18130. PubMed ID: 31628193
[TBL] [Abstract][Full Text] [Related]
12. Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice.
Hu T; Chong Y; Lu S; Qin H; Ren M; Savage NM; Chang CS; Cowell JK
Cancer Res; 2019 Jan; 79(1):114-124. PubMed ID: 30413411
[TBL] [Abstract][Full Text] [Related]
13. Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.
Ren M; Qin H; Wu Q; Savage NM; George TI; Cowell JK
Int J Cancer; 2016 Aug; 139(4):836-40. PubMed ID: 27005999
[TBL] [Abstract][Full Text] [Related]
14. SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.
Wu Q; Bhole A; Qin H; Karp J; Malek S; Cowell JK; Ren M
Oncotarget; 2016 Aug; 7(31):49733-49742. PubMed ID: 27391347
[TBL] [Abstract][Full Text] [Related]
15. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.
Cai B; Liu Y; Chong Y; Zhang H; Matsunaga A; Fang X; Pacholczyk R; Zhou G; Cowell JK; Hu T
Mol Cancer; 2021 Dec; 20(1):165. PubMed ID: 34906138
[TBL] [Abstract][Full Text] [Related]
16. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia.
Gu TL; Goss VL; Reeves C; Popova L; Nardone J; Macneill J; Walters DK; Wang Y; Rush J; Comb MJ; Druker BJ; Polakiewicz RD
Blood; 2006 Dec; 108(13):4202-4. PubMed ID: 16946300
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation.
Peiris MN; Meyer AN; Nelson KN; Bisom-Rapp EW; Donoghue DJ
Haematologica; 2020 May; 105(5):1262-1273. PubMed ID: 31439673
[TBL] [Abstract][Full Text] [Related]
18. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
19. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome.
Liu Y; Cai B; Chong Y; Zhang H; Kemp CA; Lu S; Chang CS; Ren M; Cowell JK; Hu T
Cell Death Dis; 2020 Oct; 11(10):884. PubMed ID: 33082322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
